A clinician-facing microbiome report for fibromyalgia
SomaBiome Labs is developing a clinician-facing microbiome report to support earlier identification and triage in fibromyalgia workups.
One-page clinician report designed for rapid review and triage. Built on peer-reviewed fibromyalgia and microbiome research, including PAIN and Neuron, with clinical cohorts in Montréal and Israel.
Clinical decision support under development. Not for consumer use.
The clinical gap
Fibromyalgia diagnosis is often delayed by years
Fibromyalgia affects up to 4% of adults. The workup relies on excluding competing conditions, repeated negative testing and specialist referrals over months to years. Clinicians currently have no objective biomarker to support earlier identification and triage in specialty care.
Report output
Report output
Fibromyalgia likelihood score (research-stage)
Interpretable microbial markers (direction + context)
QA flags + limitations (not diagnostic)
Research grounding
Study Participants
2019 retrospective cohort · 77 FM, 79 controls
Peer-reviewed
PAIN 2019 · PAIN 2022 · Neuron 2025
Clinical cohorts
Montréal, QC · Haifa, Israel
Research stage
Prospective validation is the next step.
Partnership Inquiries
We are currently speaking with clinicians and specialty sites interested in pilot collaboration, workflow fit, and early clinical evaluation.
Clinical collaboration inquiryClinical decision support under development. Not for consumer use.